Compare Iris Energy Limited (IREN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iris Energy Limited vs ResMed Inc. — how do they compare? Iris Energy Limited trades at $35.19 (market cap $14.07B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.3× Iris Energy Limited's market cap, and ResMed Inc. pays a 1.16% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and ResMed Inc. for 51 Days on average.
| IREN | RMD | |
|---|---|---|
Market Cap | $14.07B | $31.89B |
Volume | 54,492,460 | 618,314 |
Sector | Technology | Health |
52-Week High | $76.41 | $277.88 |
52-Week Low | $29.31 | $182.82 |
Typical Hold Time | 28 Days | 51 Days |
Enterprise Value | $16.02B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IREN shares are trading at $35.19, down 9.05% in the last 24 hours, reflecting ongoing investor concerns despite strong analyst optimism. The stock shows bearish technical signals with key support at $33, while fundamental metrics reveal a challenging profitability picture with a negative net income margin of -99.38% despite revenue growth projections. Recent news highlights the company's aggressive pivot from Bitcoin mining to AI infrastructure, backed by multi-billion dollar contracts with Microsoft and NVIDIA.
The investment case hinges on execution of IREN's ambitious AI infrastructure expansion, with JPMorgan projecting $24 billion in annual revenue by 2030. However, significant risks include ballooning losses, high capital expenditure requirements, and intense competition in the neocloud space. Despite 80% analyst buy ratings and an $81 consensus price target suggesting 130% upside, the stock faces near-term pressure from missed earnings and negative cash flow trends.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
